Lilly to acquire Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program - Investors | Eli Lilly and Company
The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.
Comments